2023 Need a response to the following Therapy guidelines for H Pylori Treatment H Pylori remains to be

Need a response to the following: 

Therapy guidelines for H. Pylori Treatment

H. Pylori remains to be one of the most common chronic bacterial infection affecting humans. Research shows that H. Pylori is normally acquired during childhood, with most victims being those who are socially disadvantaged and people who have migrated to North America (Chey et al., 2017). Although currently, there are no new drugs that have been developed, treatment primarily depends on a mixture of antibiotics and anti-secretory agents. H. Pylori treatment regimens are such as triple therapy, sequential therapy, quadruple treatment, and levofloxacin-based triple therapy (De Francesco et al., 2017). In selecting the best treatment regimen, it’s important to consider previous antibiotic exposure, the rate of eradication, and regional antibiotic-resistance patterns as these can affect the successful treatment of the condition (Myran & Zarbock, 2018). Additionally, it can be noted that for a treatment to be effective and successful, then host factors such as allergies and patient adherence need to be considered (Fashner & Gitu, 2015).

           Recent treatment guidelines have recommended quadruple therapy, which consists of PPI and three antibiotics (metronidazole, clarithromycin, and amoxicillin), which are to be administered concurrently (Chey et al., 2017). According to Shiotani et al. (2017), the rationale for this treatment option is that it’s not evidence-based but “hope-based” because gastroenterologists do believe that the infection would be susceptible to metronidazole or clarithromycin. 

           Patient compliance is a key factor that would determine treatment success. To minimize cases of side effects, clinicians should talk to their patients to adhere to their treatment plans and also instruct their patients on the right time to take their doses in relation to their meal (Li et al., 2019). Patients should be informed that they should avoid taking alcohol with metronidazole, avoid cheese, soy beans, and soy sauce taken with furazolidone (Li et al., 2019). Finally, it’s important to advice the patient to maintain personal hygiene by taking clean water and avoid ingesting contaminated food.

The original work is below in case you needed:

GI Case Study:

Chief complaint: “I have recurrent H. Pylori infection”. 

HPI: M.C. a 46-year-old Hispanic female presents to the GI clinic for complaint of recurrent H. Pylori infection. She was treated about 2 ½ months ago with H. Pylori triple therapy and failed treatment. She has PMH of dyspepsia, and GERD. She also indicates that she has noticed that her symptoms of dyspepsia are worsening for past 2 months. She has associated her symptoms with nausea, upset stomach with all foods. Denies associated symptoms of hematochezia, melena, hemoptysis, abdominal pain, fever, chills, pain or any other symptoms. 

PMH: 

H. Pylori infection gastritis

Diabetes Mellitus, type 2

Surgeries: None

Allergies: NKDA

Vaccination History: Up-to-date

Social history:

High school graduate, married and no children. He frequently eats out in restaurants. He drinks one 4-ounce glass of red wine daily. He is a former smoker that stopped 3 years ago.

Family history:

Both parents are alive. Father has history of DM type 2, Tinea Pedis. Mother alive and has history of atopic dermatitis, tinea corporis and tinea pedis. 

ROS:

Constitutional: Negative for fever. Negative for chills. 

Respiratory: No Shortness of breath. No Orthopnea. 

Cardiovascular: No edema. No palpitations. 

Gastrointestinal: No vomiting. +Dyspepsia. + Nausea. No constipation. No melena. No abdominal pain.

Physical examination:

Vital Signs

Height: 5 feet 5 inches Weight: 140 pounds BMI: 31 obesity, BP 110/70 T 98.0 po P 80 R 22, non-labored

ABDOMEN: No abdominal distention. Nontender. Bowel sounds + x 4 quadrants. No organomegaly. Normal contour; No palpable masses.

Labs day of visit:: Hgb 15.2, Hct 40%, K+ 4.0, Na+137, Serum Creatinine normal 1.0, AST/ALT normal. TSH 3.7 normal, glucose 98 normal

Assessment:

Primary Diagnosis: Recurrent H. Pylori infection gastritis

Secondary Diagnoses: Dyspepsia

Differential Diagnosis: Peptic Ulcer Disease

Previous medication plan: two months ago and failed.

1. Clarithromycin      500 mg po BID for 2 weeks
2. Omeprazole      40 mg po BID for 2 weeks and then po daily.
3. Cipro      500 mg po BID for 2 weeks

Plan: Tests

Pt had EGD done 2 weeks ago that showed H. Pylori positive gastritis in biopsy results. 

Urea breath test 8 weeks after treatment with H. Pylori medications. Pt needs to stop PPI’s 2 weeks prior to Urea Breath test. 

Labs: No new labs are needed.  

Referrals: may refer based on effect of medication therapy given for 2 weeks.

Follow up: return to office in 8 weeks to reevaluate symptoms.

As a future nurse practitioner, it is important that you determine the medications used for recurrent H. Pylori infection. 

Please discuss new therapy guidelines for H. Pylori treatment, and provide patient education.